APPY News Alert Aspenbio Pharma (APPY) 1.70 12/25/2014 04:30

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aspenbio Pharma (APPY) 1.70 $APPY

Venaxis Files Response to FDA's Request for Additional Information
PR Newswire - Wed Dec 03, 3:35PM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood-based test designed to aid emergency room clinicians in identifying children, adolescent, and young adult patients who are at low risk for appendicitis, today announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission. Venaxis will provide a business update, including discussion on the APPY1 FDA submission, on Monday, December 8, 2014, at 4:30 p.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.70 (+0.04)

Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:32AM CST
Venaxis, Inc. (APPY) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
ICUI: 83.38 (+1.63), GWPH: 68.08 (+1.82), APPY: 1.70 (+0.04), OSUR: 10.26 (+0.25)

Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum
PR Newswire - Thu Nov 13, 3:15PM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will be presenting at the Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum being held in New York on November 20, 2014.
APPY: 1.70 (+0.04)

Venaxis: Latest Clinical Data Reveals Huge Market Potential
Blair O'Neill - Seeking Alpha - Wed Oct 29, 10:48AM CDT
Introduction The APPY1 test is a 20 minute diagnostic tool that can be used to rule out the presence of acute appendicitis for the expected price of $80. Venaxis' ( APPY ) goal for the APPY1 test is to reduce the number of CT scans, the use of...
APPY: 1.70 (+0.04)

Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14
PR Newswire - Mon Oct 27, 3:30PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14). The clinical trial involved 29 U.S. hospital sites recruiting patients aged 2 - 20 from January 2013 through January 2014. Results were presented by Lead Principal Investigator Dr. David S. Huckins, M.D.
APPY: 1.70 (+0.04)

Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14
PR Newswire - Tue Oct 14, 3:05PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced that results of the company's pivotal APPY1 clinical trial will be presented by Dr. David S. Huckins, M.D., Lead Principal Investigator, at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
APPY: 1.70 (+0.04)

Venaxis to Present at September Investor Conferences
PR Newswire - Thu Aug 28, 8:15AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will present at three upcoming investor conferences: the Rodman & Renshaw 16th Annual Global Investment Conference being held in New York on September 8-10, 2014, the Aegis Capital 2014 Healthcare & Technology Conference being held in Las Vegas on September 10-13, 2014, and the 5th Annual Craig-Hallum Alpha Select Conference being held in New York on September 18, 2014.
APPY: 1.70 (+0.04)

Venaxis to Provide Business Update, including FDA Submission Update
PR Newswire - Thu Aug 07, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will provide a business update, including discussion on the progress of the APPY1 FDA submission, on Monday, August 11, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.70 (+0.04)

Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference
PR Newswire - Tue Aug 05, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 34th Annual Growth Conference, to be held August 13-14, 2014, at the Intercontinental Boston in Boston, MA.
APPY: 1.70 (+0.04)

AspenBio Pharma Down 15.9%, Shares Slide into the Red (APPY)
Comtex SmarTrend(R) - Wed Jul 16, 10:07AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 15.9% to $1.88 on 6.3x average daily volume. AspenBio Pharma has traded 1.3 million shares thus far today, vs. average volume of 206,000 shares per day. The stock has underperformed the Dow (-15.9% to the Dow's 0.2%) and underperformed the S&P 500 (-15.9% to the S&P's 0.2%) during today's trading.
APPY: 1.70 (+0.04)

Venaxis Reports on Recent FDA Submission Activities
PR Newswire - Wed Jul 16, 8:15AM CDT
CASTLE ROCK, Colo., July 16, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, updated on recent activities concerning its U. S. Food and Drug Administration (FDA) submission for the APPY1 Test that was filed in March 2014. The FDA has reviewed the submission, and provided Venaxis with questions and information requests on the submission.
APPY: 1.70 (+0.04)

Venaxis to Present at ICV Company Outreach Summit
PR Newswire - Tue Jul 01, 3:10PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will participate in the third annual ICV Company Outreach Summit, being held July 9-10, 2014, in Montauk, New York. Steve Lundy, President and CEO of Venaxis® will be presenting at the conference to investors including representatives from hedge and private equity funds as well as high net worth individuals and family funds.
APPY: 1.70 (+0.04)

REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
CBI: 41.94 (-0.17), ARLP: 42.33 (+0.35), ALOG: 86.43 (+0.32), BJRI: 49.15 (+0.22), CENTA: 9.30 (+0.06), APPY: 1.70 (+0.04)

NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
APPY: 1.70 (+0.04), ALL: 70.69 (-0.06)

Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
APPY: 1.70 (+0.04)

Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
MDT: 74.08 (+0.31), SIMG: 5.31 (-0.07), MWW: 4.56 (-0.11), APPY: 1.70 (+0.04), NYT: 13.41 (-0.17), AAPL: 112.01 (-0.53), RFMD: 16.59 (+0.29), LF: 4.72 (+0.05)

Spinnaker Support Achieves Record Results and Market Traction in 2013
PR Newswire - Thu Jan 23, 6:00AM CST
Spinnaker Support, a global market leader for SAP, JD Edwards, and Siebel third-party maintenance, application/technical management services, and consulting, today announced a year of tremendous growth as a result of its record-breaking sales and market share gains.
APPY: 1.70 (+0.04)

Social Media Marketing University Announces Its December 2013 Master Certification Program Graduates
PR Newswire - Wed Jan 15, 7:30AM CST
Social Media Marketing University (SMMU) announced today that 8 students received their Master Certification in December. Each student was required to take six core courses and two electives, and pass the program exam. Students have up to one year to complete the program.
APPY: 1.70 (+0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 21

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 44

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking AI Potential: VERSES Genius™ Surpasses Competitors

Updated Category News Views 353

VERSES Genius™ Agent Sets New Benchmark in AI Performance VERSES AI Inc., a pioneer in cognitive computing, is redefining intelligent systems with its innovative Genius™ toolkit. Recent evaluations against industry-leading benchmarks highlight its significant advancements in artificial intelligence. The preliminary results regarding the "Atari 100K Challenge" showcase...

Continue Reading
MKS Instruments Achieves Loan Repricing and Adds Prepayment

Updated Category News Views 356

MKS Instruments Achieves Loan Repricing and Adds Prepayment MKS Instruments, Inc. (NASDAQ: MKSI), a prominent global leader in enabling technologies, has made a significant leap in optimizing its financial structure. Recently, the company announced it has completed the repricing of its considerable secured tranche B term loans, which amount to a staggering $2.5 billion...

Continue Reading
Incredible Growth of Cheniere Energy: A 15-Year Journey

Updated Category News Views 238

The Remarkable Performance of Cheniere Energy Cheniere Energy, known by its trading symbol LNG, has consistently outperformed the market over the past 15 years. Investors in LNG have witnessed an incredible annualized return of 35.23%, exceeding the market by 22.77%. Currently, Cheniere Energy boasts a market capitalization of $53.26 billion, marking its growth trajectory...

Continue Reading
Adhara and ioBuilders Form New Powerhouse in Blockchain Solutions

Updated Category News Views 420

Adhara and ioBuilders Unite for Blockchain Innovation Adhara and ioBuilders have merged their expertise to create a leading provider of blockchain software products tailored specifically for financial institutions. This strategic alliance has resulted in a profitable company with a robust workforce of over 120 employees, distributed across various regions including the...

Continue Reading
Legal Action Against Lineage, Inc. Following Significant Stock Drop

Updated Category News Views 227

Overview of the Situation Surrounding Lineage, Inc. In recent times, Lineage, Inc. has found itself at the heart of a significant legal controversy following a dramatic 17% drop in its stock price. Leading with this news is the announcement of a class action lawsuit against the company and some of its top executives. Legal firm Bleichmar Fonti & Auld LLP is rallying...

Continue Reading